Undisclosed investors have supplied series D funding for the Tsinghua-backed bookkeeping and taxation software developer.
The UC Berkeley spinout-derived genetic eye disease therapeutics company has launched with fresh funding featuring new and founding investors.
UPenn, Penn Medicine and OUP all contributed to an oversubscribed series A round for UPenn spinout Interius Biotherapeutics.
Based on research at Stanford, Bluestar Genomics is working on a non-invasive test for pancreatic cancer.
Appia Bio has emerged from stealth with $52m in series A financing to commercialise cancer treatments based on research at UCLA.
UChicago once again invested in Kin Insurance, participating in a $63.9m series C round that brought its overall funding to nearly $150m.